Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimod… (NCT07653269) | Clinical Trial Compass
RecruitingNot Applicable
Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation
Singapore1,500 participantsStarted 2025-10-18
Plain-language summary
The purpose of this research study is to evaluate a new screening procedure for the early detection and monitoring of Age-related Macular Degeneration (AMD) in community settings and community hospital settings, to identify associated risk factors, and develop personalized monitoring strategies for at-risk individuals throughout the 5 years follow up period, which will allow us to establish prevalence, natural history of progression of early AMD in the community.
Who can participate
Age range
55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 55 years or older
* No severe systemic illnesses that prevent study participation
* Willing and able to undergo protocol-required procedures for both eyes
* Willing and able to provide written informed consent
Exclusion Criteria:
* Systemic disorders that preclude reliable clinical examination or multimodal imaging
* Poor compliance or severe mental illness that hinders participation
* Persons who are unable to give informed consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is focused on studying Asian elderly patients with AMD — am I the right age, background, and stage of AMD to even be considered for something like this?
2Since this is a natural history and observation study rather than a treatment trial, what does that mean for me practically — will I receive any treatment through this study, or is it purely about monitoring and data collection?
3The trial involves multimodal imaging, genetic testing, and metabolomic analysis — how often would I need to come in for these assessments, and is that level of commitment realistic given my current health and lifestyle?
4Given that this study is about predicting who progresses from early to late AMD, what would happen if my condition worsens during the study — would I be guided toward treatment, or would I need to seek that separately?
5Since standard treatments and monitoring options already exist for AMD, should I be pursuing those first, and could participating in this observational study run alongside or interfere with any treatment plan you might recommend for me?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To establish the natural history of AMD in Asian elderly and to identify clinical multimodal imaging, genetic, and metabolomic predictors of progression.